Working party membership and contributors
From Cancer Guidelines Wiki
Clinical practice guidelines for the diagnosis and management of melanoma > Working party membership and contributors
Management Committee
| Member name | Position |
|---|---|
| Professor John Thompson AO | Executive Director, Melanoma Institute Australia (until December 2016); Senior Surgeon, Melanoma Institute Australia; Professor of Melanoma and Surgical Oncology, The University of Sydney |
| Professor Michael Henderson | Professor of Surgery, University of Melbourne; Co-Chair, Melanoma and Skin Service, Peter MacCallum Cancer Centre, VIC |
| Professor John Kelly | Dermatologist, Victorian Melanoma Service, Alfred Hospital, Melbourne |
| Professor Georgina Long | Co-Medical Director, Melanoma Institute Australia (from December 2016); Medical Oncologist and Professor of Melanoma Medical Oncology and Translational Research, Melanoma Institute Australia and The University of Sydney, NSW |
| A/Professor Susan Neuhaus | General Surgeon and Surgical Oncologist, Royal Adelaide Hospital; Clinical Associate Professor, University of Adelaide Department of Surgery; Associate Professor, Conflict Medicine, University of Adelaide, SA |
| Dr Annette Pflugfelder | PhD Student, Dermatology Research Centre, School of Medicine, The University of Queensland |
| Professor Richard Scolyer | Conjoint Medical Director, Melanoma Institute Australia (from December 2016); Clinical Professor, Pathology, The University of Sydney, NSW |
| Professor Graham Stevens | Director of Radiation Oncology, Orange General Hospital, NSW |
| Jutta Thwaites | Head, Clinical Guidelines Network (until November 2016) |
| Laura Wuellner | Acting Head, Clinical Guidelines Network (from November 2016) |
For details of Working Party authorship and subcommittee membership, please see the membership for each guideline question.
Membership: Multidisciplinary Working Party
The Management Committee established a multidisciplinary working party to develop these guidelines (*denotes Management Committee member in the table below).
The multidisciplinary Working Party consists of the Management Committee members, the lead authors for guideline sections, consumer representatives as well as the Cancer Council Australia Project team members.
| Role | Name | Specialty/position |
|---|---|---|
| Chair of working party* | Professor John Thompson AO | Executive Director, Melanoma Institute Australia (until December 2016); Senior Surgeon, Melanoma Institute Australia; Professor of Melanoma and Surgical Oncology, The University of Sydney, NSW |
| Lead Author | A/Professor Andrew Barbour | General Surgeon, Greenslopes Private Hospital, Princess Alexandra Hospital, QLD |
| Lead Author | Dr Matteo Carlino | Medical Oncologist Westmead and Blacktown Hospitals, Melanoma institute Australia
Clinical Senior lecturer, University of Sydney, NSW |
| Lead Author | Dr David Gyorki | Consultant Surgeon, Peter MacCallum Centre, VIC |
| Lead Author* | Professor Michael Henderson | Professor of Surgery, University of Melbourne; Co-Chair, Melanoma and Skin Service, Peter MacCallum Cancer Centre, VIC |
| Lead Author | A/Professor Angela Hong | Radiation Oncologist, Melanoma Institute Australia; Clinical Associate Professor, Medicine, The University of Sydney, NSW |
| Lead Author | Dr Julie Howle | Clinical Senior Lecturer, Surgery, The University of Sydney, NSW |
| Lead Author | A/Professor T Michael Hughes | Associate Professor, Surgery, The University of Sydney; Surgeon, Sydney Adventist Hospital, NSW |
| Lead Author | Professor Richard Kefford AM | Professor of Cancer Medicine, Macquarie University, NSW |
| Lead Author* | Professor John Kelly | Dermatologist, Victorian Melanoma Service, Alfred Hospital, Melbourne, VIC |
| Lead Author* | Professor Georgina Long | Co-Medical Director, Melanoma Institute Australia (from December 2016); Medical Oncologist and Professor of Melanoma Medical Oncology and Translational Research, Melanoma Institute Australia and The University of Sydney, NSW |
| Lead Author | Professor Graham Mann | Chair, University of Sydney Cancer Research Network and Cancer MDI
Co-Director, Centre for Cancer Research, Westmead Institute of Medical Research Chair, Research Committee, Melanoma Institute Australia, University of Sydney, NSW |
| Lead Author | Dr Victoria Mar | Dermatologist and Director, Victorian Melanoma Service, Alfred Health, Melbourne, VIC |
| Lead Author | Professor Scott Menzies | The Sydney Melanoma Diagnostic Centre, Royal Prince Alfred Hospital; Professor, Discipline of Dermatology, The University of Sydney, NSW |
| Lead Author | Professor Michael Millward | Professor of Clinical Cancer Research, The University of Western Australia; Consultant Medical Oncologist, Sir Charles Gardiner Hospital, WA |
| Lead Author | Dr Rachael Morton | Director of Health Economics, NHMRC Clinical Trials Centre, The University of Sydney, NSW |
| Management Committee member | A/Professor Susan Neuhaus | General Surgeon and Surgical Oncologist, Royal Adelaide Hospital; Clinical Associate Professor, University of Adelaide Department of Surgery; Associate Professor, Conflict Medicine, University of Adelaide, SA |
| Management Committee member | Dr Annette Pflugfelder | Research Higher Degree Student, The School of Medicine, The University of Queensland, QLD |
| Lead Author | Dr Robyn Saw | Senior Lecturer, Surgery, The University of Sydney; Surgical Oncologist; General Surgeon, Melanoma Institute Australia and Royal Prince Alfred & Mater Hospitals, NSW |
| Management Committee member | Professor Richard Scolyer | Conjoint Medical Director, Melanoma Institute Australia (from December 2016); Clinical Professor, Pathology, The University of Sydney, NSW |
| Lead Author | A/Professor Michael Sladden | Dermatologist, Tas Derm, TAS |
| Lead Author | Professor H Peter Soyer | Director, School of Medicine, University of Queensland, QLD |
| Lead Author | A/Professor Andrew Spillane | Associate Professor, Surgical Oncology, The University of Sydney, NSW |
| Lead Author* | Professor Graham Stevens | Director of Radiation Oncology, Orange General Hospital, NSW |
| GP representative | Dr Margaret Hardy | General practitioner Gladesville Medical, NSW |
| GP representative | Dr Paul Fishburn | General practitioner, NSW |
| Consumer representative | Alison Button-Sloan | Patient advocate, VIC |
| Consumer representative | Clinton Heal | Patient advocate, CEO and Founder, Melanoma WA, 2011 WA Young Australian of the Year, WA |
| CCA Project Team Lead* | Jutta Thwaites | Head, Clinical Guidelines Network (until November 2016) |
| CCA Project Team Lead * | Laura Wuellner | Acting Head, Clinical Guidelines Network (from November 2016) |
Cancer Council Australia Project Team
| Role | Member name | Specialty/position |
|---|---|---|
| CCA Project Team member | Jutta Thwaites | Head, Clinical Guidelines Network |
| CCA Project Team member | Laura Wuellner | Project Manager, Clinical Guidelines Network (until November 2016); Acting Head, Clinical Guidelines Network (from November 2016 to January 2018) |
| CCA Project Team member | Katrina Anderson | Project Manager, Clinical Guidelines Network (from November 2016 to December 2017) |
| CCA Project Team member | Tamsin Curtis | Project Manager, Clinical Guidelines Network (from March 2018) |
| CCA Systematic Literature Reviewer Team member | Jackie Buck | Project Officer, Systematic Literature Reviews, Melanoma Guidelines (from project commencement until April 2016) |
| CCA Systematic Literature Reviewer Team member | Lani Teddy | Project Officer, Systematic Literature Reviews, Melanoma Guidelines (from project commencement until December 2016) |
| CCA Systematic Literature Reviewer Team member | Lyndal Alchin | Project Officer, Systematic Literature Reviews, Melanoma Guidelines (from project commencement until December 2016) |
| CCA Systematic Literature Reviewer Team member | Tamsin Parrish | Project Officer, Systematic Literature Reviews, Melanoma Guidelines (from June 2016 to December 2017) |
| CCA Systematic Literature Reviewer Team member | Meghna Kakani | Project Officer, Systematic Literature Reviews, Melanoma Guidelines (from January 2017 to December 2017) |
| CCA Systematic Literature Reviewer Team member | Cecilia Taing | Project Officer, Systematic Literature Reviews, Melanoma Guidelines (from January 2017) |
Subcommittee membership for each guideline question
For each guideline question, the guideline question lead author under consultation with the Management Committee established a subcommittee with relevant expert members of the working party and co-opted additional external clinical experts as required.
The role of the subcommittee is to review the draft content for the guideline questions of the section before it is presented to the working party.
Identification and management of high-risk individuals
| What are the genetic determinants of high risk for new primary melanoma? | |
| Question lead: Professor Graham Mann | |
| Subcommittee members | |
| Dr Anne Cust | Senior Research Fellow, Public Health, The University of Sydney, NSW |
| Professor Diona Damian | Professor of Dermatology, The University of Sydney, NSW |
| Professor H Peter Soyer | Director, School of Medicine, University of Queensland, QLD |
| Professor David Whiteman | Senior Principal Research Fellow and Head, Cancer Control, Queensland Institute of Medical Research Berghofer Medical Research Institute, QLD |
| Dr Paul Fishburn | GP, The Village Medical Practice, NSW |
| Professor John Kelly | Dermatologist, Victorian Melanoma Service, Alfred Hospital, VIC |
| Dr Rachael Morton | Director of Health Economics, NHMRC Clinical Trials Centre, The University of Sydney |
| Dr Victoria Mar | Dermatologist and Director, Victorian Melanoma Service, Alfred Health, VIC |
Diagnosis
| What are the clinical features of melanoma and how do atypical melanomas present? | |
| Question lead: Dr Victoria Mar | |
| Subcommittee members | |
| Dr Alex Chamberlain | Dermatologist, The Alfred Hospital, VIC |
| Professor Stephen Lee AM | Professor of Dermatology, The University of Sydney, NSW |
| Dr Bill Murray | Head of Anatomical Pathology, Peter MacCallum Cancer Centre, VIC |
| Professor John Kelly | Dermatologist, Victorian Melanoma Service, Alfred Hospital, Melbourne |
| What is the role of dermoscopy in melanoma diagnosis?
What is the role of sequential digital dermoscopy imaging in melanoma diagnosis? What is the role of automated instruments in melanoma diagnosis? | |
| Question lead: Professor Scott Menzies | |
| Subcommittee members | |
| Dr Alex Chamberlain | Dermatologist, The Alfred Hospital, VIC |
| A/Professor Pascale Guitera | Senior Research Fellow, Dermatology, The University of Sydney, NSW |
| Professor H Peter Soyer | Director, School of Medicine, University of Queensland, QLD |
| What is the role of confocal microscopy in melanoma diagnosis? | |
| Question leads: A/Prof Pascale Guitera | |
| Subcommittee members | |
| Prof Scott Menzies | The Sydney Melanoma Diagnostic Centre, Royal Prince Alfred Hospital; Professor, Discipline of Dermatology, The University of Sydney, NSW |
| Dr Alex Chamberlain | Dermatologist, The Alfred Hospital, VIC |
| Prof H Peter Soyer | Director, School of Medicine, University of Queensland, QLD |
| What is the role of skin surface imaging (total body photography) in the early diagnosis of patients at high risk of developing melanoma?) | |
| Question leads: Professor John Kelly and Dr Nikki Adler | |
| Subcommittee members | |
| Dr Paul Fishburn | General practitioner |
| A/Prof Pascale Guitera | Senior Research Fellow, Dermatology,The University of Sydney |
| Clinton Heal | Patient advocate |
| Alison Button-Sloan | Patient advocate |
Biopsy
| What type of biopsy should be performed for a pigmented lesion suspicious for melanoma? | |
| Question lead: Professor John Kelly | |
| Subcommittee members | |
| Dr Trevor Beer | Histopathologist, Clinipath Pathology, WA |
| Professor Diona Damian | Professor of Dermatology, The University of Sydney, NSW |
| Jonathan Ng | Honorary Research Fellow, Victorian Melanoma Service, The Alfred Hospital, VIC |
| Dr Joseph Ohana | GP, The Village Medical Practice, NSW |
| Professor Richard Scolyer | Conjoint Medical Director, Melanoma Institute Australia (from December 2016); Clinical Professor, Pathology, The University of Sydney, NSW |
| Professor H Peter Soyer | Director, School of Medicine, University of Queensland, QLD |
| What clinical information should the clinician give the pathologist to aid diagnosis of melanoma? | |
| Question lead: Professor Richard Scolyer | |
| Subcommittee members | |
| A/Professor Brendon Coventry | Associate Professor, Department of Surgery, The University of Adelaide; Senior Consultant Surgeon, Royal Adelaide Hospital, SA |
| Professor Richard Scolyer | Conjoint Medical Director, Melanoma Institute Australia (from December 2016); Clinical Professor, Pathology, The University of Sydney, NSW |
| Professor Stephen Lee AM | Professor of Dermatology, The University of Sydney, NSW |
| Professor Catriona McLean | Director, Pathology Board, Monash University; Director, Anatomical Pathology, The Alfred Hospital, VIC |
Management of primary melanoma and lentigo maligna
| What are the recommended safety margins for radical excision of a primary melanoma (in situ) and radical excision of invasive melanomas? | |
| Question lead: A/Professor Michael Sladden | |
| Subcommittee members | |
| Dr Julie Howle | Clinical Senior Lecturer, Surgery, The University of Sydney, NSW |
| Professor Omgo Nieweg | Surgeon, Melanoma Institute Australia, NSW |
| A/ Professor Brendon Coventry | Surgeon, The University of Adelaide, Royal Adelaide Hospital |
| When is a sentinel node biopsy indicated? | |
| Question lead: Dr David Gyorki | |
| Subcommittee members | |
| A/Professor Andrew Barbour | General Surgeon, Greenslopes Private Hospital, Princess Alexandra Hospital, QLD |
| Dr Victoria Mar | Dermatologist and Director, Victorian Melanoma Service, Alfred Health, VIC |
| Dr Mark Hanikeri | Director, Western Australia Plastic Surgery Centre, WA |
| Dr Shahneen Sandhu | Medical Oncologist, Peter MacCallum Cancer Centre, VIC |
| Should patients with a positive sentinel lymph node biopsy have a complete node dissection? | |
| Question lead: A/Professor Andrew Spillane | |
| Subcommittee members | |
| Dr Frank Bruscino-Raiola | Consultant Plastic Surgeon, Alfred Health, VIC |
| Dr David Gyorki | Consultant Surgeon, Peter MacCallum Centre, VIC |
| Dr Julie Howle | Senior Lecturer, Surgery, The University of Sydney, NSW |
| Dr Chris McCormack | Consultant Dermatologist, St Vincents Hospital Melbourne, VIC |
| A/Professor Mark Smithers | Associate Professor, Department of Surgery, The University of Queensland, QLD |
| What are the most effective treatment/management interventions to improve outcomes in patients with lentigo maligna? | |
| Question lead: Professor H Peter Soyer | |
| Subcommittee members | |
| A/Professor Pascale Guitera | Senior Research Fellow, Dermatology, The University of Sydney, NSW |
| A/Professor Angela Hong | Radiation Oncologist, Melanoma Institute Australia; Clinical Associate Professor, Medicine, The University of Sydney, NSW |
| Professor Richard Scolyer | Conjoint Medical Director, Melanoma Institute Australia (from December 2016); Clinical Professor, Pathology, The University of Sydney, NSW |
| A/Professor Jonathan Stretch AM | Associate Professor of Melanoma and Skin Oncology, The University of Sydney, NSW |
| Dr Geoff Strutton | Anatomical Pathologist, Princess Alexandra Hospital, QLD |
| What is the optimal management for primary desmoplastic and neurotropic melanomas?
What is the role of sentinel node biopsy for desmoplastic melanoma? | |
| Question lead: A/Professor T Michael Hughes | |
| Subcommittee members | |
| Professor John Kelly | Dermatologist, Victorian Melanoma Service, Alfred Hospital, Melbourne |
| Professor Richard Scolyer | Conjoint Medical Director, Melanoma Institute Australia (from December 2016); Clinical Professor, Pathology, The University of Sydney, NSW |
| A/Professor Jonathan Stretch AM | Associate Professor of Melanoma and Skin Oncology, The University of Sydney, NSW |
| Dr David Gyorki | Consultant Surgeon, Peter MacCallum Centre, VIC |
| A/Professor Angela Hong | Radiation Oncologist, Melanoma Institute Australia; Clinical Associate Professor, Medicine, The University of Sydney, NSW |
| Dr Alex Varey | Staff Specialist, Department of Plastic and Maxillofacial Surgery, Westmead Hospital, Sydney, Australia |
Melanoma in children
| HOW SHOULD MELANOMA IN CHILDHOOD BE MANAGED? | |
| Question lead: Dr Chris McCormack | |
| Subcommittee members | |
| Rachel Conyers | |
| Professor Richard Scolyer | Conjoint Medical Director, Melanoma Institute Australia (from December 2016); Clinical Professor, Pathology, The University of Sydney, NSW |
| Friyana Bhabha | |
| Saxon Smith | |
Management of melanocytic tumour of unknown malignant potential
| HOW SHOULD MELANOCYTIC TUMOUR OF UNKNOWN MALIGNANT POTENTIAL (MELTUMP) BE MANAGED? | |
| Question lead: Dr Alex Varey | |
| Subcommittee members | |
| Name | Position/speciality |
| Professor Richard Scolyer | Conjoint Medical Director, Melanoma Institute Australia (from December 2016); Clinical Professor, Pathology, The University of Sydney, NSW |
| Professor John Thompson AO | Executive Director, Melanoma Institute Australia (until December 2016); Senior Surgeon, Melanoma Institute Australia; Professor of Melanoma and Surgical Oncology, The University of Sydney |
Melanoma in pregnancy
| HOW SHOULD MELANOMA IN PREGNANCY BE MANAGED? | |
| Question lead: Dr Julie Howle | |
| Subcommittee members | |
| A/Professor Kiarash Khosrotehrani | Clinical Scientist, Centre for Clinical Research, The University of Queensland, QLD |
| Dr Robyn Saw | Senior Lecturer, Surgery, The University of Sydney; Surgical Oncologist; General Surgeon, Melanoma Institute Australia and Royal Prince Alfred & Mater Hospitals, NSW |
Investigations and follow-up
| WHAT INVESTIGATIONS SHOULD BE PERFORMED FOLLOWING A DIAGNOSIS OF PRIMARY CUTANEOUS MELANOMA FOR ASYMPTOMATIC STAGE I AND II PATIENTS? | |
| Question lead: Dr Rachael Morton | |
| Subcommittee members | |
| A/Professor Andrew Barbour | General Surgeon, Greenslopes Private Hospital, Princess Alexandra Hospital, QLD |
| Dr Victoria Mar | Dermatologist and Director, Victorian Melanoma Service, Alfred Health, VIC |
| A/Professor Mark Smithers | Associate Professor, Department of Surgery, The University of Queensland, QLD |
| WHAT INVESTIGATIONS SHOULD BE PERFORMED WHEN IN TRANSIT AND/OR REGIONAL NODE DISEASE (STAGE III MELANOMA) IS DIAGNOSED? | |
| Question lead: Dr Robyn Saw | |
| Subcommittee members | |
| Dr Andrew Haydon | Medical Oncologist, Alfred Hospital and Cabrini Health, VIC |
| Professor Grant McArthur | Head, Molecular Oncology Laboratory and Translational Research Laboratory, Co-Chair, Melanoma and Skin Service, Peter MacCallum Cancer Centre, VIC |
| Dr Alex Menzies | Medical Oncologist, Royal North Shore Hospital, NSW |
| Dr John Spillane | General Surgeon, Epworth Eastern Consulting, VIC |
| WHAT INVESTIGATIONS SHOULD BE PERFORMED WHEN STAGE IV MELANOMA IS DIAGNOSED? | |
| Question lead:Professor Michael Millward | |
| Subcommittee members | |
| Dr Victoria Atkinson | Senior Staff Specialist, Princess Alexandra Hospital; Visiting Medical Oncologist, Greenslopes Private Hospital, QLD |
| Dr Michael Brown | Medical Oncologist, Royal Adelaide Hospital, SA |
| Dr Andrew Haydon | Medical Oncologist, Alfred Hospital and Cabrini Health, VIC |
| Dr Alex Menzies | Medical Oncologist, Royal North Shore Hospital, NSW |
| HOW SHOULD PATIENTS AT EACH STAGE OF MELANOMA BE FOLLOWED AFTER INITIAL DEFINITIVE TREATMENT? WHAT ARE THE IDEAL SETTINGS, DURATION AND FREQUENCY OF FOLLOW-UP FOR PATIENTS WITH MELANOMA? | |
| Question lead: A/Professor Andrew Barbour | |
| Subcommittee members | |
| A/Professor Alexander Guminski | Associate Professor, Medicine, The University of Sydney, Medical Oncologist, Melanoma Institute Australia, North Shore Private Hospital, and Royal North Shore Hospital, NSW |
| Wenyuan Liu | Dermatologist, Alfred Hospital, Peter MacCallum Cancer Centre, Victorian Melanoma Service, VIC |
| Professor Scott Menzies | The Sydney Melanoma Diagnostic Centre, Royal Prince Alfred Hospital; Professor, Discipline of Dermatology, The University of Sydney, NSW |
| Dr Rachael Morton | Director of Health Economics, NHMRC Clinical Trials Centre, The University of Sydney |
Treatment for macroscopic nodal metastasis
| WHAT IS THE APPROPRIATE TREATMENT FOR MACROSCOPIC (I.E. DETECTABLE CLINICALLY OR BY ULTRASOUND) NODAL METASTASIS? | |
| Question lead: Professor Michael Henderson | |
| Subcommittee members | |
| A/Professor T Michael Hughes | Associate Professor, Surgery, The University of Sydney; Surgeon, Sydney Adventist Hospital, NSW |
| A/Professor Mark Smithers | Associate Professor, Department of Surgery, The University of Queensland, QLD |
| A/Professor Andrew Spillane | Associate Professor, Surgical Oncology, The University of Sydney |
| Dr John Spillane | General Surgeon, Epworth Eastern Consulting, VIC |
Treatment for satellite and in-transit metastatic melanoma
| WHAT ARE THE MOST EFFECTIVE TREATMENTS FOR SATELLITE AND IN TRANSIT METASTATIC MELANOMA? | |
| Question lead: Professor Michael Henderson | |
| Subcommittee members | |
| Professor Diona Damian | Professor of Dermatology, The University of Sydney, NSW |
| Professor Omgo Nieweg | Surgeon, Melanoma Institute Australia, NSW |
| Dr Robyn Saw | Senior Lecturer, Surgery, The University of Sydney; Surgical Oncologist; General Surgeon, Melanoma Institute Australia and Royal Prince Alfred & Mater Hospitals, NSW |
| A/Professor Mark Smithers | Associate Professor, Department of Surgery, The University of Queensland, QLD |
| Dr John Spillane | General Surgeon, Epworth Eastern Consulting, VIC |
Systemic therapy, immunotherapy and targeted therapies
| WHAT IS THE ROLE OF ADJUVANT SYSTEMIC THERAPY IN PATIENTS WITH RESECTED STAGE 3 MELANOMA? | |
| Question lead: Dr Matteo Carlino | |
| Subcommittee members | |
| Dr Victoria Atkinson | Senior Staff Specialist, Princess Alexandra Hospital; Visiting Medical Oncologist, Greenslopes Private Hospital, QLD |
| Professor Georgina Long | Co-Medical Director, Melanoma Institute Australia (from December 2016); Medical Oncologist and Professor of Melanoma Medical Oncology and Translational Research, Melanoma Institute Australia and The University of Sydney, NSW |
| Dr Alex Menzies | Medical Oncologist, Royal North Shore Hospital, NSW |
| Dr Robyn Saw | Senior Lecturer, Surgery, The University of Sydney; Surgical Oncologist; General Surgeon, Melanoma Institute Australia and Royal Prince Alfred & Mater Hospitals, NSW |
| Dr David Gyorki | Consultant Surgeon, Peter MacCallum Centre, VIC |
| DOES SYSTEMIC DRUG THERAPY IMPROVE PROGRESSION FREE AND/OR OVERALL SURVIVAL IN UNRESECTABLE STAGE II AND STAGE IV MELANOMA? | |
| Question lead: Professor Georgina Long | |
| Subcommittee members | |
| Dr Matteo Carlino | Medical Oncologist, The Crown Princess Mary Cancer Centre, Westmead, NSW |
| Professor Richard Kefford AM | Professor of Cancer Medicine, Macquarie University, NSW |
| Professor Grant McArthur | Head, Molecular Oncology Laboratory and Translational Research Laboratory, Co-Chair, Melanoma and Skin Service, Peter MacCallum Cancer Centre, VIC |
| Dr Alex Menzies | Medical Oncologist, Royal North Shore Hospital, NSW |
| Dr Mark Shackleton | Group Leader, Cancer Development and Treatment Laboratory, Peter MacCallum Cancer Centre, NSW |
Radiotherapy
| FOR PATIENTS WITH DISTANT METASTASIS (OTHER THAN BRAIN METASTASES), WHEN IS RADIOTHERAPY INDICATED? | |
| Question lead: A/Professor Angela Hong | |
| Subcommittee members | |
| Dr Gerald Fogarty | Director, Radiation Oncology, Mater Hospital, NSW |
| Professor Graham Stevens | Director of Radiation Oncology, Orange General Hospital, NSW |
| IS ADJUVANT RADIOTHERAPY OF VALUE FOLLOWING RESECTION OF INVOLVED LYMPH NODES? | |
| Question lead: Professor Graham Stevens | |
| Subcommittee members | |
| Professor Bryan Burmeister | Director, Radiation Oncology, Princess Alexandra Hospital, QLD |
| Dr Gerald Fogarty | Director, Radiation Oncology, Mater Hospital, NSW |
| Professor Michael Henderson | Professor of Surgery, University of Melbourne; Co-Chair, Melanoma and Skin Service, Peter MacCallum Cancer Centre, VIC |
Surgical therapy for patients with distant metastases
| For patients with distant metastases, when is surgical therapy indicated? | |
| Question lead: A/Prof Andrew Spillane | |
| Subcommittee members | |
| A/Professor Andrew Barbour | General Surgeon, Greenslopes Private Hospital, Princess Alexandra Hospital, QLD |
| Dr Julie Howle | Clinical Senior Lecturer, Surgery, The University of Sydney, NSW |
Treatment approaches to brain metastases in patients with advanced melanoma
| What is the role of systemic drug therapy in the management of patients with advanced melanoma brain metastases? | |
| Question lead: Professor Georgina Long | |
| Subcommittee members | |
| A/Professor Angela Hong | Radiation Oncologist, Melanoma Institute Australia; Clinical Associate Professor, Medicine, The University of Sydney, NSW |
| Dr Brindha Shivalingam | Director of Neurosurgery, The Chris O’Brien Lifehouse; Consultant Neurosurgeon, Royal Prince Alfred Hospital and The Mater Hospital North Sydney |
| Dr Matteo Carlino | Medical Oncologist, The Crown Princess Mary Cancer Centre, Westmead, NSW |
| Professor Richard Kefford AM | Professor of Cancer Medicine, Macquarie University, NSW |
| Professor Grant McArthur | Head, Molecular Oncology Laboratory and Translational Research Laboratory, Co-Chair, Melanoma and Skin Service, Peter MacCallum Cancer Centre, VIC |
| Dr Alex Menzies | Medical Oncologist, Royal North Shore Hospital, NSW |
| Dr Mark Shackleton | Group Leader, Cancer Development and Treatment Laboratory, Peter MacCallum Cancer Centre, NSW |
| What is the recommended surgical treatment of brain metastases in patients with advanced melanoma? | |
| Question lead: Dr Brindha Shivalingam | |
| Subcommittee members | |
| Professor Georgina Long | Co-Medical Director, Melanoma Institute Australia (from December 2016); Medical Oncologist and Professor of Melanoma Medical Oncology and Translational Research, Melanoma Institute Australia and The University of Sydney, NSW |
| A/Professor Angela Hong | Radiation Oncologist, Melanoma Institute Australia; Clinical Associate Professor, Medicine, The University of Sydney, NSW |
| When is radiotherapy indicated for patients with distant brain metastases? | |
| Question lead: A/Prof Angela Hong | |
| Subcommittee members | |
| Professor Georgina Long | Co-Medical Director, Melanoma Institute Australia (from December 2016); Medical Oncologist and Professor of Melanoma Medical Oncology and Translational Research, Melanoma Institute Australia and The University of Sydney, NSW |
| Dr Brindha Shivalingam | Director of Neurosurgery, The Chris O’Brien Lifehouse; Consultant Neurosurgeon, Royal Prince Alfred Hospital and The Mater Hospital North Sydney |
Mucosal melanoma
| What is the appropriate treatment of mucosal melanoma? | |
| Question lead: Professor Michael Henderson |
Ocular melanoma
| What is the appropriate treatment of ocular melanoma? | |
| Question lead: A/Prof Max Conway | |
| Subcommittee members | |
| Dr Michael Giblin | Clinical Senior Lecturer, Clinical Opthalmology & Eye Health, Central Clinical School |
| Dr Svetlana Cherepanoff | Consultant Pathologist & Leader, Ophthalmic Pathology Research Group, Brain and Mind Centre, The University of Sydney |
Multidisciplinary care
| IS MULTIDISCIPLINARY CARE OF VALUE IN THE MANAGEMENT OF MELANOMA? | |
| Question lead: Prof John Thompson & Dr Gabrielle Williams |
Acknowledgement
Sincere thanks to Professor Ian Olver AM who initiated the Melanoma Guidelines Revision Project in collaboration with Melanoma Institute Australia in 2014 in his role as Chief Executive Officer, Cancer Council Australia. Since February 2015, he has been Director, Sansom Institute for Health Research.